| abstract |
The present invention provides a novel method for treating cancer tumors applicable to endocrine therapy, which uses FGFR inhibitor (S)-1-(3-(4-amino-3-((3,5-dimethoxy) Phenyl)ethynyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)pyrrolidin-1-yl)prop-2-en-1-one or a pharmaceutically acceptable salt thereof. Further, there is provided a pharmaceutical composition, and related compounds, uses, methods, and combinations, the pharmaceutical composition containing the aforementioned compound or a pharmaceutically acceptable salt thereof for treating and/or preventing tumors applicable to endocrine therapy, And it is characterized by being used in combination with endocrine therapy. |